| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c1a6e42a947b3cc993d98069673d4002 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 |
| filingDate |
2014-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5872a0972a2d903645c63f4ab258aef5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9b5084eec223885c6454a1f1e5e3809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4340c24c8be4cc7fd71642f27e0f30c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a95738ee62cfb65467d4020b737ac165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7020d0495776a82bb68a56c96b8496d1 |
| publicationDate |
2015-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015064898-A1 |
| titleOfInvention |
Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation |
| abstract |
The present invention relates to a topical anti-inflammatory pharmaceutical composition with zileuton cream formulation. More particularly, the zileuton cream formulation is suitable for topical treatment of skin diseases caused by leukotriene since the zileuton cream formulation can maintain stability at room temperature and can be topically applied, thereby maximizing the pharmacological effect while minimizing the whole body absorption so as to minimize toxicity caused by a compound. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021121645-A1 |
| priorityDate |
2013-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |